Thornburg Investment Management Inc. Has $88.80 Million Position in Astrazeneca Plc $AZN

Posted by George Bondi on Jun 15th, 2026

Thornburg Investment Management Inc. reduced its position in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 1.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 505,985 shares of the company’s stock after selling 4,962 shares during the quarter. Astrazeneca accounts for 1.1% of Thornburg Investment Management Inc.’s investment portfolio, making the stock its 22nd biggest holding. Thornburg Investment Management Inc.’s holdings in Astrazeneca were worth $88,800,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in AZN. Brighton Jones LLC raised its stake in Astrazeneca by 93.2% during the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after purchasing an additional 2,789 shares during the period. AQR Capital Management LLC raised its stake in Astrazeneca by 45.3% during the 1st quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock valued at $2,756,000 after purchasing an additional 11,690 shares during the period. Amundi raised its stake in Astrazeneca by 54.4% during the 2nd quarter. Amundi now owns 10,274 shares of the company’s stock valued at $731,000 after purchasing an additional 3,618 shares during the period. Jump Financial LLC raised its stake in Astrazeneca by 898.4% during the 2nd quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock valued at $2,339,000 after purchasing an additional 30,125 shares during the period. Finally, Daiwa Securities Group Inc. raised its stake in Astrazeneca by 1.2% during the 2nd quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock valued at $3,259,000 after purchasing an additional 559 shares during the period. 20.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

AZN has been the topic of several recent analyst reports. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research note on Tuesday, June 9th. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 9th. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $205.33.

Check Out Our Latest Stock Analysis on AZN

Astrazeneca Trading Up 0.0%

NYSE AZN opened at $178.79 on Monday. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $277.28 billion, a PE ratio of 26.85, a price-to-earnings-growth ratio of 1.55 and a beta of 0.25. The firm’s fifty day simple moving average is $189.26 and its 200-day simple moving average is $186.07.

Astrazeneca (NYSE:AZN – Get Free Report) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The business had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. As a group, sell-side analysts anticipate that Astrazeneca Plc will post 9.39 earnings per share for the current fiscal year.

About Astrazeneca

(Free Report)

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.